Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide

被引：0

作者：

Orkin, Chloe ^{[1
]}

Antinori, Andrea ^{[2
]}

Rockstroh, Juergen ^{[3
]}

Guillen, Santiago Moreno ^{[4
]}

Martorell, Claudia ^{[5
]}

Molina, Jean-Michel ^{[6
]}

Lazzarin, Adriano ^{[7
]}

Maggiolo, Franco ^{[8
]}

Yazdanpanah, Yazdan ^{[9
]}

Andreatta, Kristen ^{[10
]}

Huang, Hailin ^{[10
]}

Hindman, Jason ^{[10
]}

Martin, Hal ^{[10
]}

Baeten, Jared ^{[10
]}

Pozniak, Anton ^{[11
]}

机构：

[1] Queen Mary Univ London, London, England

[2] Natl Inst Infect Dis, Lazzaro Spallanzani, Rome, Italy

[3] Univ Hosp Bonn, Bonn, Germany

[4] Hosp Ramon & Cajal, Madrid, Spain

[5] Res Inst Springfield, Springfield, MO USA

[6] Univ Paris, Paris, France

[7] San Raffaele Hosp Milan, Milan, Italy

[8] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy

[9] AP HP Hop Bichat, Paris, France

[10] Gilead Sci Inc, Foster City, CA USA

[11] Chelsea & Westminster Hosp, London, England

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

P002

引用

页码：21 / 22

页数：2

共 50 条

[21] Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis
Moore, Sarah E.
Huesgen, Emily
Howe, Zachary
INTERNATIONAL JOURNAL OF STD & AIDS, 2020, 31 (03) : 285 - 287
[22] Clinical efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide and lamivudine/dolutegravir in the treatment-na?ve patients with acquired immunodeficiency syndrome
王江蓉
China Medical Abstracts(Internal Medicine), 2024, 41 (03) : 157
[23] An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir plus abacavir/lamivudine
Rogatto, Felipe
Bouee, Stephane
Jeanbat, Vivianne
Piontkowsky, David
Aragao, Filipa
Bosse, Matthew
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 175 - 176
[24] The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz
Asif, Sumbul
Baxevanidi, Evangelia
Hill, Andrew
Venter, Willem Daniel Francois
Fairlie, Lee
Masenya, Masebole
Serenata, Celicia
Sokhela, Simiso
Chandiwana, Nomathemba
AIDS, 2021, 35 : S117 - S125
[25] Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
Eric S. Daar
Chloe Orkin
Paul E. Sax
Debbie Hagins
Anton Pozniak
Kimberly Workowski
Cynthia Brinson
Juan Manuel Tiraboschi
Hui Liu
Chris Deaton
Cal Cohen
Sharline Madera
Jason T. Hindman
Moti Ramgopal
AIDS Research and Therapy, 22 (1)
[26] Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
Podzamczer, D.
Mican, R.
Tiraboschi, J.
Portilla, J.
Domingo, P.
Llibre, J. M.
Ribera, E.
Vivancos, M. J.
Morano, L.
Masia, M.
Gomez, C.
Fanjul, F.
Payeras, A.
Inciarte, A.
Estrada, V
Rivero, A.
Castro, A.
Bernal, E.
Vinuesa, D.
Knobel, H.
Troya, J.
Macias, J.
Montero, M.
Sanz, J.
Navarro-Alcaraz, A.
Caicedo, A.
Fernandez, G.
Martinez, E.
Moreno, S.
OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (03):
[27] Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide
Lowman, E.
Hardigan, P.
Unger, N.
Lee, N.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 75 - 75
[28] Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
Lin Gan
Xiaoxin Xie
Yanhua Fu
Xiaoyan Yang
Shujing Ma
Linghong Kong
Chunli Song
Yebing Song
Tingting Ren
Hai Long
Infectious Diseases and Therapy, 2023, 12 : 2581 - 2593
[29] Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults
Mendoza, Ines
Lazaro, Alicia
Espinosa, Alfredo
Sanchez, Lorenzo
Horta, Ana Maria
Torralba, Miguel
PLOS ONE, 2023, 18 (09):
[30] Comparison of dolutegravir plus Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice
Gan, Lin
Xie, Xiaoxin
Fu, Yanhua
Yang, Xiaoyan
Ma, Shujing
Kong, Linghong
Song, Chunli
Song, Yebing
Ren, Tingting
Long, Hai
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (10) : 877 - 884

← 1 2 3 4 5 →